Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$5.02

52W Range

$1.57 - $19.95

50D Avg

$4.07

200D Avg

$4.45

Market Cap

$326.29M

Avg Vol (3M)

$1.37M

Beta

-0.70

Div Yield

-

AMLX Company Profile

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

384

IPO Date

Jan 07, 2022

Website

AMLX Performance

AMLX Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$380.79M	$22.23M	$285.00K
Operating Income	$38.80M	$-201.34M	$-82.69M
Net Income	$49.27M	$-198.38M	$-87.88M
EBITDA	$39.89M	$-201.34M	$-82.69M
Basic EPS	$0.73	$-3.39	$-1.59
Diluted EPS	$0.70	$-3.39	$-1.59

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q3 24Nov 09, 24 | 10:06 AM

Q2 24Aug 09, 24 | 9:02 AM

Q1 23Jul 10, 24 | 2:23 PM

Peer Comparison

Ticker	Company
XFOR	X4 Pharmaceuticals, Inc.
MREO	Mereo BioPharma Group plc
DAWN	Day One Biopharmaceuticals, Inc.
PDSB	PDS Biotechnology Corporation
HOOK	HOOKIPA Pharma Inc.
TERN	Terns Pharmaceuticals, Inc.
INZY	Inozyme Pharma, Inc.
ABOS	Acumen Pharmaceuticals, Inc.